NASDAQ:IDRA - Idera Pharmaceuticals Stock Price, Forecast & News

Idera Pharmaceuticals trades on the NASDAQ under the ticker symbol "IDRA."

Idera Pharmaceuticals shares reverse split on the morning of Monday, July 30th 2018. The 1-8 reverse split was announced on Friday, July 27th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 27th 2018. An investor that had 100 shares of Idera Pharmaceuticals stock prior to the reverse split would have 13 shares after the split.

Idera Pharmaceuticals Inc (NASDAQ:IDRA) released its quarterly earnings results on Wednesday, November, 6th. The biotechnology company reported ($0.39) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.47) by $0.08. View Idera Pharmaceuticals' Earnings History.

Idera Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for Idera Pharmaceuticals.

3 brokers have issued 1 year price targets for Idera Pharmaceuticals' stock. Their forecasts range from $7.00 to $14.00. On average, they expect Idera Pharmaceuticals' stock price to reach $9.33 in the next year. This suggests a possible upside of 418.5% from the stock's current price. View Analyst Price Targets for Idera Pharmaceuticals.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Idera Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Idera Pharmaceuticals.

Press coverage about IDRA stock has trended somewhat negative recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Idera Pharmaceuticals earned a news sentiment score of -1.7 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Idera Pharmaceuticals.

Idera Pharmaceuticals saw a increase in short interest in November. As of November 15th, there was short interest totalling 600,200 shares, an increase of 18.2% from the October 31st total of 507,900 shares. Based on an average daily trading volume, of 137,300 shares, the days-to-cover ratio is currently 4.4 days. Approximately 2.6% of the company's stock are sold short. View Idera Pharmaceuticals' Current Options Chain.

Some companies that are related to Idera Pharmaceuticals include LogicBio Therapeutics (LOGC), Dyadic International (DYAI), Nantkwest (NK), Aptose Biosciences (APTO), X4 Pharmaceuticals (XFOR), Windtree Therapeutics (WINT), Fennec Pharmaceuticals (FENC), Gamida Cell (GMDA), Adaptimmune Therapeutics (ADAP), Novavax (NVAX), Champions Oncology (CSBR), Brainstorm Cell Therapeutics (BCLI), La Jolla Pharmaceutical (LJPC), Cidara Therapeutics (CDTX) and Axcella Health (AXLA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Idera Pharmaceuticals investors own include Oasis Petroleum (OAS), BioCryst Pharmaceuticals (BCRX), Novavax (NVAX), Anavex Life Sciences (AVXL), Verastem (VSTM), Proteostasis Therapeutics (PTI), Inovio Pharmaceuticals (INO), TrovaGene (TROV), Celldex Therapeutics (CLDX) and Synergy Pharmaceuticals (SGYP).

Idera Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Millennium Management LLC (3.26%) and Tower Research Capital LLC TRC (0.05%). Company insiders that own Idera Pharmaceuticals stock include Bryant David Lim, Carol Schafer, Invest Corp Pillar, James A Geraghty, Joanna Horobin and Vincent Milano. View Institutional Ownership Trends for Idera Pharmaceuticals.

IDRA stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC and Tower Research Capital LLC TRC. Company insiders that have bought Idera Pharmaceuticals stock in the last two years include Bryant David Lim, Carol Schafer, James A Geraghty, Joanna Horobin and Vincent Milano. View Insider Buying and Selling for Idera Pharmaceuticals.

Shares of IDRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of IDRA stock can currently be purchased for approximately $1.80.

Idera Pharmaceuticals has a market capitalization of $51.97 million and generates $660,000.00 in revenue each year. The biotechnology company earns $-59,880,000.00 in net income (profit) each year or ($2.28) on an earnings per share basis. Idera Pharmaceuticals employs 36 workers across the globe.View Additional Information About Idera Pharmaceuticals.

The official website for Idera Pharmaceuticals is http://www.iderapharma.com/.

Idera Pharmaceuticals' mailing address is 505 EAGLEVIEW BLVD. SUITE 212, EXTON PA, 19341. The biotechnology company can be reached via phone at 484-348-1600 or via email at [email protected]